Overview

Fluoxetine in Pediatric Body Dysmorphic Disorder

Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This trial will study the effectiveness of the medication fluoxetine for children and adolescents ages 16 and younger with BDD who qualify.
Phase:
Phase 4
Details
Lead Sponsor:
Montefiore Medical Center
Collaborator:
Food and Drug Administration (FDA)
Treatments:
Fluoxetine